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SUMMARY 
Background: Anecdotally, increasing number of pa-
tients are seen at Korle Bu Teaching Hospital (KBTH) 
with brain tumour. Neuro-ophthalmic symptoms and 
signs may help in timely diagnosis and intervention. 
Objective: To evaluate the neuro-ophthalmic and clin-
ical characteristics of brain tumour in patients present-
ing at a tertiary hospital in Ghana. 
Study design: A prospective case series involving 36 
consecutive patients newly diagnosed with brain tu-
mour from November 2010 to October 2011, at the 
Ophthalmology, Neurosurgery and Endocrine units of 
KBTH, Ghana. All patients had clinical diagnosis of 
brain tumour with confirmation by computerized to-
mography (CT) or magnetic resonance imaging (MRI). 
Thirteen patients had histological confirmation of di-
agnosis. 
Outcome measures: Presenting Visual acuity, Colour 
vision, Visual fields and Cranial nerve deficits. 
Results: Data of 36 patients were analyzed. Ages 
ranged from 3 to 69years, mean (SD) 42.56(±16.6 
years). Twenty-six (72%) were females. Tumours in-
cluded pituitary adenoma (20,55.5%), meningio-
ma(10,27.8%), choroid plexus tumour(1,2.8%), medul-
loblastoma(1,2.8%),craniopharyngioma(1,2.8%), hae-
mangioblastoma(1,2.8%), thalamic tumour(1,2.8%) 
and haemangioma(1,2.8%). Histologically confirmed 
tumours included pituitary adenoma (9, 69.2%), men-
ingioma (3, 23.1%), craniopharyngioma (1, 7.7%). One 
patient had both a pituitary adenoma and meningioma. 
Blurred vision (30, 83.3%), headache (28, 77.8%) and 
photophobia (13, 36.1%) were predominant symptoms. 
Commonest neuro-ophthalmic signs were impaired 
colour vision (62 eyes, 88.6%), optic atrophy (26, 
74.3%), unilateral or bitemporal hemianopia (15, 
41.5%) and relative afferent pupillary defect (12, 
34.3%). Seven (19.4%) patients were visually impaired 
and nine (25%) blind. Thirty-three of 72(45.8%) eyes 
had monocular blindness. 
Conclusions: Common neuro-ophthalmic characteris-
tics were blurred vision, headache, impaired colour 
vision, optic atrophy, and relative afferent pupillary 
defect (RAPD). Significant numbers of patients were 
blind or visually impaired at presentation. 
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INTRODUCTION 
 Primary intracranial tumours are a leading cause of 
morbidity and mortality in patients with neurological 
disease.1,2 Clinical features are caused by mass effect, 
irritation raised intracranial pressure or influence of 
hormones.2The visual pathway and ocular nerves are 
not exempt from these effects.1,2,3 
 
Neuro-ophthalmic manifestations may help diagnose 
tumours since the ophthalmologist may be the first 
point of call for patients with this tumours.1,4,5 Anecdo-
tally, increasing number of patients are seen at Korle 
Bu Teaching Hospital (KBTH) with brain tumours. 
This study purposed to determine the neuro-ophthalmic 




A prospective case series involving 36 consecutive 
patients newly diagnosed with brain tumours seen from 
November 2010 to October 2011 at the KBTH, Accra, 
Ghana were studied. Ethical approval was obtained 
from the Ethical and Protocol Review Committee of 
the University of Ghana Medical School. Patients and 
carers who did not consent to participation were ex-
cluded from the study.  
 
 







All patients had clinical diagnosis of brain tumour with 
confirmation by either CT or MRI. Some patients had 
in addition, histological confirmation of diagnosis.   
 
Demographic (age, sex, community of residence, histo-
ry of symptoms), clinical (ophthalmic, endocrine, neu-
rologic,) and histopathological data were recorded us-
ing a predesigned questionnaire. 
 
Ophthalmic evaluation 
This included visual acuity (VA) tested using appropri-
ate test type for age: fixation methods and/or Cardiff 
cards for preverbal children(≤ 2years) matching tests 
such as Animal Snellen’s  and Sheridan Gardner charts 
for pre-schoolers (3- 5 years) Snellen’s charts (for both 
literate and illiterate) for children over 5 years and 
adults. For patients who were unable to see the letters 
at the closest test distance, the following test sequence 
was used: count fingers (CF) at 1 m, hand movement 
(HM) at 1 m, light perception (LP) and no light percep-
tion (NLP).  
 
Best corrected Visual Acuity with spectacles (BCVA 
)was recorded using WHO categories of visual im-
pairment adapted from the International Classification 
of Diseases (9th revision, 1975), visual status was  
graded as: 
(a) ‘Blind’ when visual acuity (VA) was <3/60 
(b) ‘Impaired’ when VA was <6/18–3/60   
(c) ‘Normal’ when VA was 6/6–6/18. 
 
Colour vision was tested using Ishihara Colour Vision 
Charts (38 Plate Edition 1994). External eye examina-
tions included careful evaluation for proptosis using 
Hertel’s exophthalmometer (G.Rodenstock Instrument; 
Munchen Hamburg, Germany) as well as assessment of 
ocular movements, diplopia and nystagmus. Anterior 
segment assessment included slit lamp examination 
using (Topcon ATE-600 2004, Japan), pupil reaction to 
light and relative afferent pupillary defect.  
 
Fundus examination was done using biomicroscopy 
with a + 90D lens, indirect ophthalmoscope with +20D/ 
+28D lenses and  direct ophthalmoscope through dilat-
ed pupils (using tropicamide 1%, and or cyclopentolate 
eye drops 1% with phenylephrine 2.5% eye drops).  
Visual field was assessed using a Humphrey visual 
field analyser (SITA,Carl Zeiss Meditec; Dublin 
CA.USA, 2005). Assessment of the size of the tumour 
was done radiologically using Computerised Tomogra-
phy scan (CT scan) Hitachi Eclos -2009 or Magnetic 
resonance imaging (MRI) Hitachi Airis elite (OPEN). 
 
Endocrine evaluation: 
This included clinical examination of patients by the 
endocrinologist and assessment of anterior pituitary 
hormones namely luteinising hormone(LH), follicle 
stimulating hormone(FSH), 9am serum cortisol , pro-
lactin (PRL), triiodothyronine(free T3), thyroxin(free 
T4), and thyroid stimulating hormone(TSH). 
 
Neurosurgical evaluation:   
Neurosurgical evaluation by neurosurgeons involved 
history and examination of the nervous system. The 
mental state, cranial nerves, coordination, motor and 
sensory examinations were performed for each patient. 
 
Outcome measures 
Outcome measures studied included presenting Visual 
acuity, Colour vision, Visual fields and Cranial nerve 
deficits. 
 
Statistical Data Analysis 
Data was captured using Microsoft Access and ana-
lysed using Statistical Package for Social Scientists 
(SPSS) Version 16.0. Continuous numeric data were 
summarized as Mean and Standard deviation (SD) and 
categorical data as percentages (%). Results were pre-
sented as frequencies, tables and charts.  
 
To prove significant outcomes, t-test was used to com-
pare mean levels of visual acuity between right and left 
eyes. Mann-Whitney Test was used for establishing 
significant association between, duration before 
presentation and, visual acuity, optic atrophy and 
RAPD.  Correlation was used to assess linear relation-
ship between tumour location and optic atrophy. 
 
Chi-squared was used to compare proportions, at 0.05 
significant levels. Logistic regression analysis was used 
to establish significant association between visual acui-
ty and tumour type and size.   
 
RESULTS  
Data on 36 patients were analyzed. Thirty three 
(91.7%) were adults and three (8.3%) children. Ages 
ranged from 3 to 69 years (mean/SD 42.6 years±16.6) 
with median age of 43.5years. Twenty-six (72 %) were 
females.  The duration of symptoms before presenta-
tion ranged from one to eighty-four months with mean 
of 8.7 and a median duration of 4.5 months.   
 
Pattern of referral 
Greater proportions (14, 38.9%) of patients were re-
ferred by Neurosurgeons at Korle Bu Teaching Hospi-
tal (KBTH) followed by peripheral general hospitals 















Table 1 Pattern of referral to eye clinic 
 
General neurologic presentation 
Headache (28, 77.8%) was the commonest general 
symptom reported. ‘Others’(7,19.4%) in Table 2 in-
cluded  right hemiparesis (2), memory loss(1), hoarse-
ness of voice(1), static attacks(1), lid retraction(1) and 
left lower limb paresis(1). 
 











7(19.4) Seizure 4(11.1) 
Anosmia 7(19.4) Tinnitus  4(11.1) 
Amenorrhoea 7(19.4) Motor palsy 4(11.1) 
Other  7(19.4) Nausea 3(8.3) 
Vomiting  5(13.9) Ataxia 2(5.6) 




Two (2) patients had been detained at a psychiatry hos-
pital for five and three years respectively for abnormal 
behaviour with an impaired sensorium or amnesia re-
spectively.  
 
General ocular signs and symptoms 
The commonest ocular symptom was visual blur (30, 
83.3%). Other common complaints were photophobia 
(11, 31.4%) and ocular pain (11, 31.4%).  
 
All four patients with proptosis had meningioma. Two 
of these patients died, one after surgery and the other 
before scheduled surgery. Cause of death was uncon-
firmed because they were lost to follow up. 
 
Neuro-ophthalmic signs 
Impaired colour vision was the commonest neuro oph-
thalmic sign in this study. Sixty-two of 70(88.6%) eyes 
had impaired colour vision. There was however no 
significant association between duration before presen-
tation and degree of colour vision in the right 
(p=0.271) or left (p=0.369) eyes. Two patients did not 
have colour vision recorded, one of these had impaired 
sensorium from a massive frontal lobe tumour and the 
other was a three year old child who could not read the 
colour plates. 
 
Other neuro-ophthalmic signs were optic atrophy (26, 
74.3%), RAPD (12, 34.3%) and swollen optic discs (9, 
25 %) (Table3) There was no significant association 
between duration before presentation and either RAPD 
(p=0.220) or optic atrophy (p=0.118) in either eye. 
 















Visual blur 5(13.9 4(11.1) 21(58.3) 30(83.3) 
Ocular pain 3(8.3) 6(16.7) 2(5.6) 11(30.6) 
Red Eye 0(0) 1(2.8) 0(0.0) 1(2.9) 
Photophobia 1(2.9) 1(2.8) 11(30.6) 13(36.1) 
NEUROOPHTHALMIC     
Proptosis 4(11.1) 0(0.0) 0(0.0) 4(11.1) 
Diplopia 0(0.0) 0(0.0) 1(2.9) 1(2.9) 
Optic disc swelling 2(5.6) 1(2.8) 6(16.7) 9(25.0) 
Optic disc atrophy 5(13.9) 2(5.8) 19(52.8) 26(74.3) 
Normal optic disc 1(2.9) 0(0.0) 3(8.3) 4(11.4) 
Ptosis  2(5.7) 0(0.0) 0(0.0) 2.(5.7) 
RAPD 5(14.3) 7(20) 0(0.0) 12(34.3) 
Ocular nerve palsy 2(5.7) 0(0.0) 5(14.3) 7(20.0) 
Nystagmus 0(0.0) 0(|0.0) 1(2.9) 1(2.9) 
Strabismus 0(0.0) 0(0.0) 1(2.9) 1(2.9) 
Shunt vessels on disc 1(2.9) 0(0.0) 0(0.0) 1(2.9) 
 
 
Table 4 Imaging diagnosis and visual field type 
Tumour type N (%) Visual field type N (%) 
Meningioma 10(27.8) Uni/bitemporal 
hemianopia 
15(45.5) 
Pituitary adenoma 20(55.5) Normal  
Choroid plexus tu-
mour 
1(2.8) Total field loss 4(12.1) 
Medulloblastoma 1(2.8) Superior quadran-
tanopia 
2(6.1) 
Haemangioblastoma 1(2.8) Junctional scoto-
ma 
2(6.1) 
Craniopharyngioma  1(2.8) Homonymous 
hemianopia 
1(3.0) 
Thalamic tumour 1(2.8) Inferior altitudinal 1(3.0) 
Haemangioma 1(2.8) Inferior arcuate 1(3.0) 
Total  36(100) Non specific 
 visual field  
1(3.0) 
  Total number with 
visual fields done 
33(100) 
 
Blindness and visual impairment at presentation 
Nine (25%) patients were bilaterally blind. Monocular 
blindness occurred in 33 of 72 (45.8%) eyes. Most eyes 
(45, 62.5%) examined were either visually impaired or 
blind.  
Source of Referral Number of 
patients (%) 
Neurosurgeon 14 (38.9) 
Peripheral general hospitals 12(33.2) 
Endocrinologist 4 (11.1) 
Gynaecologist 2 (5.6) 
Psychiatrist 2(5.6) 
Private eye clinic 2(5.6) 
Total 36 (100) 
 
 








There was no significant difference in blindness or 
visual impairment between right and left eyes 
(p=0.726).There was also no significant association 
found between time before presentation and visual acu-
ity (p=0.288). 
 
The commonest visual field defects detected in this 
series, were unilateral or bitemporal hemianopia (15, 
41.5%).Other visual fields are shown in Table 4.  
 
Tumour location and type 
Majority (28, 77.8%) of the tumours were parasella in 
location followed by the temporo-parietal part of the 
brain (4, 11%). There was no significant association 
found between tumour location and optic atrophy 
(p=0.505) or visual acuity (p=0.257). Pituitary adeno-
ma (20, 55.5%) and meningioma (10, 27.8%) were the 
commonest tumours in this study. (Table 4) All ten 
cases of meningioma were females. Tumours in the 
three children in this study were craniopharyngioma, 
medulloblastoma and choroid plexus tumour however, 




Fourteen (48.3%) of 29 patients who had anterior pitui-
tary homone analysis had high prolactin levels above 




Intracranial tumours are second only to stroke as the 
leading cause of death from neurological disease.1In 
developing countries severe to complete visual loss 
from optic atrophy has been described due to late 
presentation.2,4 Ophthalmic signs and symptoms occur 
as an initial presentation in up to fifty percent of pa-
tients diagnosed with primary brain tumours in 
adults2,4,5,6 and up to 39 to 43% in children.7 Children 
however  present with less specific symptoms than 
adults.7 
 
In this series 30(83.3%) patients presented with blurred 
vision. This corroborates other studies which reported 
reduced vision.1,3,8 Pituitary adenoma and meningioma 
were the most common tumours in this series as was 
the case in some series, 3,8but this is in contrast with 
other studies which reported meningioma as the com-
monest.1,2,4,9,10,11This difference in our series may be 
due to diagnosis of the patients confirmed mostly by 
neuroimaging studies rather than histologically.  
 
Only 13 of our patients had histological confirmation 
of diagnosis because they could not afford surgery. The 
shorter duration of recruitment in this study in compar-
ison with other series with longer duration in recruit-
ment1,2,3,4 may also be a contributory factor. Most tu-
mours in this series were located in the parasella and 
temporo-parietal part of the brain as was the case in a 
Kenyan series.4 
 
The male: female ratio was 1: 2.6 which is similar to 
findings from other studies1,12  However, it is in con-
trast with observations from Nigeria, 2,13  which shares 
similar geographic and demographic features in the 
West African Sub-region. The greater number of fe-
males in this study may be due to general female pre-
ponderance of meningiomas and pituitary adeno-
mas.1,3,8,13,14,15 The disparity in sex distribution between 
this study and the Nigerian studies may also be at-
tributed to the bulk (83.3%) of tumours in this study 
being meningiomas and pituitary adenomas whereas 
this group of tumours constituted 52.1% and 39.8% in 
Onapoya’s 2 and Idowus’s series13 respectively.  
 
All the patients with meningioma in this series were 
females which are similar to findings in other series 
which report a female preponderance for meningio-
mas.2,13,15 This mean age of presentation in this study is 
similar to a study in Nigeria 13 but higher than other 
studies.1,2   
 
 A greater number of patients were referred from the 
neurosurgeon as opposed to Onapoya’s series in which 
a similar percentage of 40.9% were from private hospi-
tals.2 The greater referral from the neurosurgeon in our 
series may be due to the neurosurgeons routine of re-
ferring patients with brain tumours for ophthalmic 
evaluation before surgery. The primary source of refer-
ral may have been from other hospitals and clinics and 
the neurosurgeon may have been the secondary referral 
source.  
 
Two patients were referred from the psychiatrist at 
advanced stages having been kept there for three to five 
years before diagnosis. These patients got referred to 
the ophthalmologist only when they complained of 
poor vision. Psychiatric symptoms as was found in 
these two patients is not uncommon and indeed, symp-
toms like depression, hallucination and personality 
changes in patients with intracranial tumours are well 
documented.10, 12  
  
This study shares a variability in duration of symptoms 
before presentation with some series 2, 3, 8 but differs 
from them in not having any presentation within days.  
The most common presentations were blurred vision, 
headache and photophobia.  
Blurred vision 30(83.3%) as seen in this study is well 
documented in many other series of patients studied 
with brain tumours.1, 2, 3,4,7,8 
 
 







Majority (28, 77.8%) of our patients reported headache 
at presentation. This is a recognized symptom manifest 
in 43% to 99% of patients with brain tu-
mour.1,4,10,12,16,17,18 Monocular blindness 33 of 
72(45.8%) eyes was commoner than bilateral blindness 
as was the case in one larger study.8 Of the 72 eyes 
examined in this series majority 45(62.5%) were either 
visually impaired or blind. This is similar to a study in 
Kenya 4 but not others.2,3 The authors attribute the 
higher number of  blind  or visual impaired  to primary 
optic atrophy as a result of compression from pituitary 
adenoma  and meningioma which were the common 
tumours seen in this study as well as to late presenta-
tion of patients. Late presentation in this study is simi-
lar to what pertains in other studies in developing coun-
tries.2,4 Visual loss in pituitary adenoma and meningi-
oma turns to be insidious.3,16 Subtle visual deficits es-
pecially when unilateral are often underestimated and 
may be attributed to aging or stress and imaging per-
formed only when damage is severe.19  
 
The number of bilaterally blind in our series was how-
ever lower than that of Kilthisak’s larger series in Thai-
land.3  Tumours in the sella region are known to cause 
severe visual loss due to their close proximity to vital 
neurovascular structures particularly the optic chi-
asm20This difference between the two studies is diffi-
cult to explain ,but may be due to small sample sizes. 
Further studies may be necessary. Post-operative im-
provement in vision is disappointing in patients with 
severe visual impairment associated with optic atro-
phy.20 This however, is not unexpected as the optic 
nerve does not regenerate. Limited resources for neu-
roimaging and surgery are of great concern since in 
Ghana, initiation of appropriate and early therapy fur-
ther delay the burden of severe visual impairment and 
blindness from these tumours. This study however, did 
not find any significant association between tumour 
site and visual acuity (p=0.257).  
 
This differs from a study in Kenya which found a sig-
nificant correlation between tumours compressing the 
anterior visual pathway and degree of visual impair-
ment.4 This difference is difficult to explain and further 
studies in a larger series over a longer period may be 
necessary. No significant association between time 
before presentation and visual acuity was found in this 
study (p=0.288). This is in contrast to a study from 
Nigeria.21 This may be due to large variability in time 
before presentation in a smaller sample of patients in 
this series and also that the Nigerian study was limited 
to meningioma’s. 
 
The percentage of patients with optic atrophy (74.3%) 
is similar to a series in Saudi Arabia 20 but higher than 
others.1,3,4 This higher percentage of optic atrophy may 
be explained by late presentation of patients in this 
study as well as the fact that this study, being prospec-
tive, had the advantage of thorough review of optic 
disc as opposed to the others which were retrospective 
studies in which case notes were reviewed and as such 
optic atrophy may have been missed or not document-
ed.  
 
There was however no significant association between 
duration before presentation and optic atrophy in either 
eye (p=0.118). In developing countries profound to 
complete visual loss from optic atrophy has been de-
scribed due to late presentation.2,4 This disparity of 
association between duration before presentation and 
optic atrophy in our study is difficult to explain. Fur-
ther studies may be needed to explain this. Relative 
afferent pupillary defect (RAPD) is an important sign 
in patients with optic neuropathy and may be an early 
sign of unilateral optic nerve compression in patients 
with brain tumour or asymmetric growth of a parasella 
brain tumour. RAPD was elicited in 34.3% of our pa-
tients. This was lower than that seen in other larger 
series1,3,4  
 
The lower percentage of patients with RAPD in our 
series can be explained by the higher percentage of 
bilateral optic atrophy due to late presentation and to 
most tumours in this series being parasella in location 
and thus compressing the optic chiasm. There was no 
significant association between duration before presen-
tation and RAPD (p=0.220).This may be due to the 
wide range in duration of symptoms before presenta-
tion of between one month to seven years.  
 
Colour vision defect in this series was higher than that 
seen in Marco S. et al’s series.4 in which 63% of the 
cases had colour vision defect. The higher number of 
eyes with colour vision impairment may be due to most 
cases in this series being either monocularly or bilater-
ally blind or visually impaired at presentation and as 
such were unable to recognize the colour plates shown 
them. 
 
Unilateral or bitemporal hemianopia was the common 
visual field defect in 45.5% of the 33 patients who had 
visual field test performed in this study. This is the 
typical field seen in patients with pituitary adenomas 
with compression from below.3 Thus it is not unex-
pected since a high percentage (77.8%) of patients with 
parasella tumour were seen in this series. Unilateral 
blurred vision and hemianopia seen in some patients in 
this study corroborates a study in Thailand of a similar 












Prolactin was the highest (48.3% of 29) anterior pitui-
tary hormone secreted by patients with pituitary ade-
noma in this study. This is similar to a Finnish study of 
hormones secreted by pituitary adenomas.14 
 
Strengths and limitations 
The main strengths of this study are its prospective 
nature and it being the first study to describe the neuro-
ophthalmic and clinical characteristics of brain tumours 
in this population. However, the lack of histological 
confirmation of diagnosis in some patients and the 
small numbers studied were recognized limitations.  
 
CONCLUSION   
Pituitary adenoma and meningioma are the common 
intracranial tumours seen in Ghana. Though blurred 
vision and headache are common early symptoms, di-
agnosis is not made till very late due to late presenta-
tion. Colour vision impairment, optic atrophy and rela-
tive afferent pupillary defect were the commonest 
signs. Most of these patients presented with monocular 
or binocular blindness or visual impairment due to late 
presentation. Education of the public as well as   physi-
cians to pick up early signs and symptoms of brain 
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